Curis, Inc. (CRIS)
Stock Price:
$1.28 USD
0.02 (1.59%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $1.29 +0.01 (0.78%) Aug 14, 7:52 PM
Key Info
| Market Cap |
68.95M |
| Revenue (ttm) |
11.21M |
| Net Income (ttm) |
-31.46M |
| Shares Out |
53.87M |
| EPS (ttm) |
-0.90 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$1.28 |
| Previous Close |
$1.26 |
| Change ($) |
0.02 |
| Change (%) |
1.59% |
| Day's Open |
1.26 |
| Day's Range |
1.24 - 1.32 |
| Day's Volume |
870,605 |
| 52-Week Range |
0.62 - 3.59 |
More Stats
| Market Cap |
68.95M |
| Enterprise Value |
53.26M |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
53.87M |
| Float |
40.89M |
| EPS (basic) |
-0.9 |
| EPS (diluted) |
-0.90 |
| FCF / Share |
-0.71 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
692,179 |
| Short Ratio |
0.51 |
| Short % of Float |
1.27% |
| Beta |
2.33 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
6.15 |
| PB Ratio |
n/a |
| Revenue |
11.21M |
| Operating Income |
-26.57M |
| Net Income |
-31.46M |
| Free Cash Flow |
-28.13M |
| Net Cash |
15.69M |
| Net Cash / Share |
0.29 |
| Gross Margin |
-114.18% |
| Operating Margin |
-236.99% |
| Profit Margin |
-280.60% |
| FCF Margin |
-250.89% |
| ROA |
-35.64% |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.67*
(264.84% upside)
Low
4.00
Current: $1.28
High
5.00
Target: 4.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 10.00 | 10.43 | 9.90 | 7.53 | 7.88 | 9.84 | 15.00 | 16.97 | 14.76 | 16.00 |
| Revenue Growth | -4.07% | 5.35% | 31.5% | -4.46% | -19.96% | -34.39% | -11.61% | 14.97% | -7.73% | - |
| Gross Profit | 9.50 | 9.87 | 9.40 | 7.13 | 7.47 | 9.50 | 14.80 | 16.80 | 14.76 | 16.00 |
| Operating Income | -24.36 | -29.33 | -49.76 | -58.04 | -56.48 | -15.86 | -9.42 | -18.62 | -7.20 | -5.64 |
| Net Income | -32.14 | -32.58 | -53.32 | -60.41 | -58.98 | -18.73 | -12.32 | -16.42 | -9.86 | -4.44 |
| Shares Outstanding | 33.18 | 33.12 | 29.83 | 26.56 | 24.67 | 17.19 | 16.47 | 15.81 | 15.27 | 14.99 |
| Earnings Per Share | -0.97 | -0.98 | -1.79 | -2.25 | -2.40 | -1.10 | -0.75 | -1.05 | -0.65 | -0.30 |
| Operating Cash Flow | -26.21 | -30.07 | -48.36 | -35.81 | -29.89 | -16.81 | -9.54 | -15.19 | -4.56 | -1.63 |
| Capital Expenditures | -0.04 | -0.09 | -0.19 | -0.33 | -0.02 | -0.09 | -0.15 | -0.10 | -0.18 | -0.18 |
| Free Cash Flow | -26.25 | -30.15 | -48.54 | -36.14 | -29.92 | -16.90 | -9.69 | -15.30 | -4.75 | -1.80 |
| Cash & Equivalents | 20.70 | 24.42 | 60.23 | 44.49 | 82.19 | 49.76 | 58.19 | 55.55 | 37.72 | 40.60 |
| Total Debt | 0.17 | 35.48 | 41.56 | 19.86 | 24.17 | 28.30 | 30.56 | 29.84 | - | - |
| Net Cash / Debt | 20.53 | -11.06 | 18.68 | 24.63 | 58.03 | 21.47 | 27.64 | 25.71 | 37.72 | 40.60 |
| Assets | 35.11 | 37.37 | 73.80 | 57.75 | 94.97 | 62.61 | 80.59 | 69.77 | 48.18 | 50.65 |
| Liabilities | 69.02 | 41.86 | 49.81 | 28.49 | 30.46 | 32.83 | 35.42 | 35.50 | 8.30 | 5.13 |
| Book Value | -33.91 | -4.50 | 23.99 | 29.27 | 64.51 | 29.78 | 45.17 | 34.27 | 39.88 | 45.52 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Curis, Inc. |
| Country |
United States |
| Employees |
28 |
| CEO |
James E. Dentzer |
Stock Information
| Ticker Symbol |
CRIS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CRIS |
| IPO Date |
August 1, 2000 |
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company also has a scientific collaboration with DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments for Fimepinostat in DLBCL and solid malignancies. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.